271 related articles for article (PubMed ID: 22352726)
1. Antidote control of aptamer therapeutics: the road to a safer class of drug agents.
Bompiani KM; Woodruff RS; Becker RC; Nimjee SM; Sullenger BA
Curr Pharm Biotechnol; 2012 Aug; 13(10):1924-34. PubMed ID: 22352726
[TBL] [Abstract][Full Text] [Related]
2. Development of universal antidotes to control aptamer activity.
Oney S; Lam RT; Bompiani KM; Blake CM; Quick G; Heidel JD; Liu JY; Mack BC; Davis ME; Leong KW; Sullenger BA
Nat Med; 2009 Oct; 15(10):1224-8. PubMed ID: 19801990
[TBL] [Abstract][Full Text] [Related]
3. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
Bompiani KM; Monroe DM; Church FC; Sullenger BA
J Thromb Haemost; 2012 May; 10(5):870-80. PubMed ID: 22385910
[TBL] [Abstract][Full Text] [Related]
4. Aptamers: the emerging class of future anticoagulation for vascular disease.
Kuliczkowski W; Floyd J; Malinin A; Serebruany V
Expert Rev Cardiovasc Ther; 2010 Apr; 8(4):503-7. PubMed ID: 20397824
[TBL] [Abstract][Full Text] [Related]
5. Rapid Complexation of Aptamers by Their Specific Antidotes.
Stoll H; Steinle H; Wilhelm N; Hann L; Kunnakattu SJ; Narita M; Schlensak C; Wendel HP; Avci-Adali M
Molecules; 2017 Jun; 22(6):. PubMed ID: 28594360
[TBL] [Abstract][Full Text] [Related]
6. Biologics: The quest for a universal antidote.
Flight MH
Nat Rev Drug Discov; 2009 Dec; 8(12):934. PubMed ID: 19967801
[No Abstract] [Full Text] [Related]
7. Antidote-controlled DNA aptamer modulates human factor IXa activity.
Fang L; Jin J; Zhang Z; Yu S; Tian C; Luo F; Long M; Zuo H; Lou S
Bioorg Chem; 2024 Jul; 148():107463. PubMed ID: 38776649
[TBL] [Abstract][Full Text] [Related]
8. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic applications of aptamers.
Kaur G; Roy I
Expert Opin Investig Drugs; 2008 Jan; 17(1):43-60. PubMed ID: 18095918
[TBL] [Abstract][Full Text] [Related]
10. An anticoagulant with light-triggered antidote activity.
Heckel A; Buff MC; Raddatz MS; Müller J; Pötzsch B; Mayer G
Angew Chem Int Ed Engl; 2006 Oct; 45(40):6748-50. PubMed ID: 16983715
[No Abstract] [Full Text] [Related]
11. Regulatable aptamers in medicine: focus on antithrombotic strategies.
Potti A; Rusconi CP; Sullenger BA; Ortel TL
Expert Opin Biol Ther; 2004 Oct; 4(10):1641-7. PubMed ID: 15461575
[TBL] [Abstract][Full Text] [Related]
12. The potential of aptamers as anticoagulants.
Nimjee SM; Rusconi CP; Harrington RA; Sullenger BA
Trends Cardiovasc Med; 2005 Jan; 15(1):41-5. PubMed ID: 15795162
[TBL] [Abstract][Full Text] [Related]
13. In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin.
Chang TW; Blank M; Janardhanan P; Singh BR; Mello C; Blind M; Cai S
Biochem Biophys Res Commun; 2010 Jun; 396(4):854-60. PubMed ID: 20452328
[TBL] [Abstract][Full Text] [Related]
14. Applications and future of aptamers that achieve rapid-onset anticoagulation.
Yu H; Frederiksen J; Sullenger BA
RNA; 2023 Apr; 29(4):455-462. PubMed ID: 36697262
[TBL] [Abstract][Full Text] [Related]
15. Reversible Aptamer Staining, Sorting, and Cleaning of Cells (Clean FACS) with Antidote Oligonucleotide or Nuclease Yields Fully Responsive Cells.
Requena MD; Yan A; Llanga T; Sullenger BA
Nucleic Acid Ther; 2024 Feb; 34(1):12-17. PubMed ID: 38285522
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology and aptamers: applications in drug delivery.
Levy-Nissenbaum E; Radovic-Moreno AF; Wang AZ; Langer R; Farokhzad OC
Trends Biotechnol; 2008 Aug; 26(8):442-9. PubMed ID: 18571753
[TBL] [Abstract][Full Text] [Related]
17. Aptamers: an emerging class of therapeutics.
Nimjee SM; Rusconi CP; Sullenger BA
Annu Rev Med; 2005; 56():555-83. PubMed ID: 15660527
[TBL] [Abstract][Full Text] [Related]
18. RNA aptamers as reversible antagonists of coagulation factor IXa.
Rusconi CP; Scardino E; Layzer J; Pitoc GA; Ortel TL; Monroe D; Sullenger BA
Nature; 2002 Sep; 419(6902):90-4. PubMed ID: 12214238
[TBL] [Abstract][Full Text] [Related]
19. Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer.
Musumeci D; Montesarchio D
Pharmacol Ther; 2012 Nov; 136(2):202-15. PubMed ID: 22850531
[TBL] [Abstract][Full Text] [Related]
20. SELEX methods on the road to protein targeting with nucleic acid aptamers.
Bayat P; Nosrati R; Alibolandi M; Rafatpanah H; Abnous K; Khedri M; Ramezani M
Biochimie; 2018 Nov; 154():132-155. PubMed ID: 30193856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
